Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Landscape of Immunotherapy Resistance in NSCLC
Daniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

Genetic profile of ferroptosis in non-small cell lung carcinoma and pharmaceutical options for ferroptosis induction
Rohil Jawed, Huma Aslam Bhatti, Adnan Khan
Clinical & Translational Oncology (2024)
Closed Access | Times Cited: 2
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
Douglas Dias e Silva, Guilherme Bes Borba, Juliana Rodrigues Beal, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4209-4209
Open Access | Times Cited: 6
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
Sukumar Kalvapudi, Yeshwanth Vedire, Sai Yendamuri, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Natural Bacterial and Fungal Peptides as a Promising Treatment to Defeat Lung Cancer Cells
Kamila Rybczyńska‐Tkaczyk, Anna Grenda, Anna Jakubczyk, et al.
Molecules (2023) Vol. 28, Iss. 11, pp. 4381-4381
Open Access | Times Cited: 5
Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
Ewa Kalinka‐Warzocha, Kamila Wojas‐Krawczyk, Paweł Krawczyk
Cancers (2023) Vol. 15, Iss. 13, pp. 3499-3499
Open Access | Times Cited: 4
RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature
Youjiao Si, Zhonghua Zhao, Xiangjiao Meng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasis
Alberto Mendoza, Ethan Dettmann, Douglas Hanes, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 1
Spon1+ inflammatory monocytes promote collagen remodeling and lung cancer metastasis through lipoprotein receptor 8 signaling
Kristina Marinak Whately, Nisitha Sengottuvel, Lincy Edatt, et al.
JCI Insight (2024) Vol. 9, Iss. 9
Open Access | Times Cited: 1
Fatty acid metabolism prognostic signature predicts tumor immune microenvironment and immunotherapy, and identifies tumorigenic role of MOGAT2 in lung adenocarcinoma
Denggang Fu, Biyu Zhang, Wenyan Fan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer
Karolina Hanna Prazanowska, Jiwon Hong, Su Bin Lim
Translational Lung Cancer Research (2023) Vol. 12, Iss. 8, pp. 1816-1821
Open Access | Times Cited: 3
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5810-5810
Open Access | Times Cited: 5
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B. Garon, Alexander I. Spira, Sarah B. Goldberg, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 8, pp. 1094-1102
Open Access | Times Cited: 2
Antibody Diversity in Cancer: Translational Implications and Beyond
Raghuram Reddy, Joel A. Mintz, Roei Golan, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1165-1165
Open Access | Times Cited: 3
ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma
Sarah Laing, Björn Kruspig, Robin Shaw, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products
Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
RILPL2 as a potential biomarker for predicting enhanced T cell infiltration in non-small cell lung cancer
Dongfang Chen, Hongyan Zhang, Lifang Zhao, et al.
Immunologic Research (2024) Vol. 72, Iss. 5, pp. 1174-1184
Open Access
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products
Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access
Herbal Medicines for the Improvement of Immune Function in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Young-Min Cho, Hwa-Seung Yoo, Soo-Dam Kim, et al.
Integrative Cancer Therapies (2024) Vol. 23
Open Access
A Novel Fatty Acid Metabolism Signature Predicts Prognoses, Tumor Immune Microenvironment, and Immunotherapy Response In Lung Adenocarcinoma
Denggang Fu, Biyu Zhang, Wenyan Fan, et al.
Research Square (Research Square) (2023)
Open Access
Preinvasive to Invasive: PD-1–Expressing Macrophages Shift Lung Cancer into High Gear
Juyeun Lee, Defne Bayık, Justin D. Lathia
Cancer Research (2022) Vol. 82, Iss. 14, pp. 2515-2516
Open Access
Identification of immune-related gene signatures to evaluate immunotherapeutic response in cancer patients using exploratory subgroup discovery
Olha Kholod
(2022)
Open Access
Previous Page - Page 2

Scroll to top